Riskpilot← Back to searchSign inGet full accessArexis AB
ABActiveOrg 5565735130112 76 StockholmResearch and experimental development on natural sciences and engineering · NACE 7210Est. 19990 employees
Revenue 2024
SEK 3,1B
+23% vs 2023
EBITDA margin
100.0%
+23% vs 2023
Equity ratio
1.7%
Financial strength
Net profit 2024
SEK 12K
-89% vs 2023
| Revenue | SEK 3,1B | +23% |
| EBITDA | SEK 3,1B | +23% |
| Net profit | SEK 12K | -89% |
| Total assets | SEK 13,4B | -8% |
| Equity | SEK 226,9M | +0% |
| Employees | 0 | — |
Legal name
Arexis AB
Org number
5565735130
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 oktober 1999
Share capital
SEK 786 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget skall bedriva biomedicinsk forskning och utveckling samt kommersialisering av biomedicinska produkter, idka handel med värdepapper samt därmed förenlig verksamhet.
Address
112 76 Stockholm
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 752 126 | 1 415 000 | 2 119 000 | 2 512 190 | 3 089 857 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 751 956 | 1 415 000 | 2 119 000 | 2 506 734 | 3 089 719 |
| Depreciation & amort. | −692 708 | −693 000 | −693 000 | −838 112 | −862 069 |
| EBIT | 1 059 248 | 722 000 | 1 426 000 | 1 668 622 | 2 227 650 |
| Net financials | −171 324 | −268 000 | −186 000 | −85 642 | −14 360 |
| Profit before tax | 0 | 0 | 0 | 109 | 12 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | 0 | 0 | 109 | 12 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 13 910 166 | 13 190 000 | 12 931 000 | 14 516 016 | 13 414 474 |
| Equity | 226 796 | 227 000 | 227 000 | 226 904 | 226 916 |
| Long-term debt | 7 068 965 | 5 679 000 | 4 029 000 | 3 409 643 | 0 |
| Short-term debt | 884 405 | 208 000 | 305 000 | 79 269 | 2 588 624 |
| Total debt | 7 953 370 | 5 887 000 | 4 334 000 | 3 488 912 | 2 588 624 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20202024
Equity ratio
1.7%
This company
38.2%
Market median
-96% vs market
20202024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
0.23×
This company
1.12×
Market median
-79% vs market
20202024
Debt / equity
58.12×
This company
0.62×
Market median
-9274% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JM Chief Auditor | Chief Auditor | 2022 |
| Former (1) | ||
BS Chief Auditor | Chief Auditor | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Swedish Orphan Biovitrum Ab (Publ)
Arexis AB Board members of Arexis AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jonatan Mattias Hansson | Chief Auditor | 0 companies |
| Björn Sture Bernhard Peters Ohlsson | Chief Auditor | 0 companies |
| Guido Oelkers | Board of Directors | 0 companies |
| Karl Henrik Stenqvist | Board of Directors | 0 companies |
| Per Richard Torbjörn Hallberg | Chairman | 0 companies |